A recent report published in the American Journal of Case Reports describes a rare case of drug reaction with eosinophilia and systemic symptoms (DRESS)-induced agranulocytosis in a patient treated with the beta-lactam antibiotic oxacillin.
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for fedratinib (Celgene), an investigational agent being developed for the treatment of myelofibrosis (MF). Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).…
A recently published report describes the case of a 49-year-old female patient who experienced aplastic anemia secondary to long-term metronidazole use and highlights the importance of monitoring for metronidazole-induced hematologic dyscrasias.
Models developed for individuals in whom aspirin is being considered for primary prevention of CVD.
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
The use of plasma infusion therapies (often called “vampire” treatments, in which people undergo infusions of a young donor’s blood) is on the rise across the United States.
Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
This is currently the only liquid formulation of this agent available in the US.
For individuals without cardiovascular disease, use of aspirin is associated with a reduced risk for cardiovascular events and an increased risk for major bleeding, according to a newly published meta-analysis.
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
